Master Class: Non-muscle Invasive Bladder Cancer - Preserving Oncologic Outcomes in Times of Shortages and New Therapies

Thursday, October 30, 2025

14:00 - 15:30 GMT+0

Co-Chair(s)

Stephen Williams

Associate Chief Medical Officer, Med Director High Value Care, Professor and Chief of Urology
University of Texas Medical Branch, USA, Texas, United States
Ahmed Ali

Consultant urological surgeon
Frimley Health NHS Foundation Trust , United Kingdom

At the end of this session, attendees should be able to:

Evaluate the role of AI modeling in NMIBC treatment prediction.
Assess emerging evidence supporting risk-adapted treatment approaches in NMIBC.
Examine evolving therapeutic approaches in NMIBC treatment continuum.
Analyze the economic impact of innovation in NMIBC management and its implications for clinical practice.

14:00 - 14:10 GMT+0

AI Path (Lotan) and AI Modeling Outcomes (Toronto)
14:10 - 14:20 GMT+0

De-intensifying Treatment Strategies for Low and Intermediate Risk Disease
Speaker: Adam S. Feldman – Massachusetts General Hospital
14:20 - 14:30 GMT+0

Will There Be a New Standard for BCG Naïve High Risk NMIBC?
Speaker: Charles Peyton – University of Alabama at Birmingham
14:30 - 14:40 GMT+0

Prevention and Management of BCG Toxicities and Patient Selection
Speaker: Niyati Lobo
14:40 - 14:50 GMT+0

Sequencing of Therapies When BCG Fails? (include BCG Reinduction)
14:50 - 15:00 GMT+0

Economic Considerations in the Management of NMIBC: Innovation Comes at What Price?
Speaker: Stephen B. Williams – University of Texas Medical Branch, USA, Texas
15:00 - 15:30 GMT+0

Cases and Discussion